ChromaDex

Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ChromaDex reports record revenue and eyes growth through partnerships

ChromaDex's strong revenue growth and positive EBITDA reflect operational improvements.
The company faces challenges in sales channels and marketing claims but sees growth opportunities.
Strategic focus on new partnerships, product development, and pharmaceutical initiatives for future growth.

ChromaDex reports robust Q1 performance, eyes innovation for growth

ChromaDex's Q1 2023 performance was strong, with notable growth in revenue and positive cash flows. The company faces challenges in recurring revenue conversion and aims for improved financial metrics. However, opportunities lie in innovation, R&D, and potential partnerships for future growth.

ChromaDex reports strong Q2 earnings and eyes market expansion

ChromaDex's Q2 performance reflects robust revenue growth, strong partnerships, and a commitment to scientific excellence, positioning the company for continued success.
While facing challenges such as customer retention and working capital management, ChromaDex remains focused on profitability and strategic investments for future growth.
Opportunities in expanding market share, leveraging key partnerships, and enhancing customer loyalty present avenues for sustained revenue growth and market leadership.
With a solid financial position and a balanced approach to growth, ChromaDex is poised to navigate challenges and capitalize on opportunities in the evolving market landscape.

ChromaDex reports robust Q3 results, eyes growth through strategic partnerships

ChromaDex's Q3 performance reflects revenue growth, profitability, and operational efficiency, supported by strong financials and strategic partnerships.
The company's focus on innovation, market expansion, and cost control measures positions it well for sustained growth and competitive advantage.
While facing challenges in a dynamic market environment, ChromaDex's opportunities lie in product innovation, market diversification, and strategic partnerships.
Overall, ChromaDex's strategic initiatives and financial strength indicate a positive outlook for future growth and market expansion.

ChromaDex reports robust earnings, eyes growth through partnerships and innovation

ChromaDex delivered strong financial performance in Q4 2023 and full year 2023, driven by revenue growth, partnerships, and product demand.
While facing challenges in meeting consumer demand and optimizing resource allocation, the company remains focused on responsible practices and future growth opportunities.
With a solid financial foundation, strategic partnerships, and a focus on innovation, ChromaDex is poised for continued growth and market leadership in the dietary supplement industry.

ChromaDex reports revenue growth and strategic partnerships for future expansion

ChromaDex's Q1 2024 performance reflects revenue growth, positive EBITDA, and strategic initiatives for future expansion.
The company's strengths lie in subscriber base building, successful product SKUs, and stable market presence in key segments.
While facing challenges such as increased expenses and short-term R&D investments, ChromaDex is well-positioned for growth.
Opportunities in new partnerships, product development, and market exploration offer avenues for revenue growth and enhanced customer value.

ChromaDex reports revenue growth and product innovation in Q2

ChromaDex's Q2 2024 performance showed revenue growth, positive EBITDA, and a strong cash position.
The company's strengths lie in its innovative NIAGEN product line and positive clinical study outcomes.
Challenges include market misinformation and the need to adjust outlook due to product delays.
Opportunities exist in addressing specific health conditions and leveraging marketing strategies for growth.

ChromaDex (CDXC) reports record Q3 results and eyes growth

ChromaDex (CDXC) delivers strong Q3 performance with record revenue and profitability, driven by e-commerce and product launches.
Despite challenges in outlook adjustment and pricing strategies, the company's financial discipline and market focus position it for growth.
Opportunities lie in expanding product reach, FDA approvals, and strategic marketing to capitalize on market potential.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ChromaDex's (CDXC) CEO Rob Fried on Q3 2020 Results - Earnings Call Transcript

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (Nasdaq:CDXC) today reported third quarter financial results. 2020 Third Quarter and Recent Highlights Total net sales of $14.2 million, up 18% from $12.1 million from the year ago quarter. Tru Niagen® net sales of $11.9 million, a 22% increase from the year ago quarter. Net loss was ($4.2) million or ($0.07) per share, an improvement of $0.05 per share year-over-year. Adjusted EBITDA excluding total legal expense, a non-GAAP measure, was a loss of

ChromaDex Corporation Reports Third Quarter 2020 Financial Results

On Wednesday, November 04, ChromaDex (NASDAQ: CDXC) will release its latest earnings report. Check out Benzinga's preview to understand the implications.

Preview: ChromaDex's Earnings

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed., November 4, 2020 at 4:30 p.m. ET to discuss its financial results for the third quarter ended September 30, 2020. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call. Investor Conference Call: ChromaDex management will host an investor conference call to discuss the third quarter resu

ChromaDex to Report Third Quarter 2020 Financial Results on Wednesday, November 4, 2020

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today highlighted a new study published in The European Molecular Biology Organization Journal looking at the effect of nicotinamide riboside (NR) on maintaining telomeres, the protective regions at the end of DNA strands. This study is the first to show that by increasing NAD+, NR helped protect telomeres which are important in addressing life-threatening telomere-related diseases, paving the way for future clinical research. The stud

New Study from NIH Finds Nicotinamide Riboside Helps Improve Telomere Dysfunction in Human Cells, Mice

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today announced its flagship ingredient, Tru Niagen®, is now available in Nestlé Health Science’s new Celltrient™ Cellular Energy, a protein-based flavored drink mix to help renew natural processes that decline as we age. The new product includes a 250mg serving of Tru Niagen® (nicotinamide riboside, or NR) and is one of three products under the new Celltrient brand. ChromaDex and Nestlé Health Science entered a global commercial licen

Celltrient™ Cellular Energy Products Featuring Tru Niagen® Launch in US

ChromaDex: Blazing Ahead Of Ponce De Leon

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today highlighted a new study from Nature Immunology that found nicotinamide riboside (NR) helped energize tumor infiltrating T-cells (TILs) in samples extracted from mice. In a preclinical mouse model, NR was shown to improve T-cell function, which is a component of new cancer immunotherapies such as PD-1 and PDL-1 inhibitors. These findings lend further data to the potential role of NR in supporting healthy mitochondrial function. T-

New Preclinical Study Finds Nicotinamide Riboside May Improve Immune Cell Function

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today announced that results from the study “Combined metabolic cofactor supplementation accelerates recovery in mild-to-moderate COVID-19” were published on the open access preprint publication server medRxiv.org. The Phase 2 study reported patients with mild-to-moderate COVID-19 experienced a 29% reduction in recovery time when receiving the standard of care in combination with a nutritional protocol including nicotinamide riboside (

ChromaDex Announces Study Results Showing Nutritional Protocol Including Nicotinamide Riboside Plus Standard of Care Reduces Recovery Time in COVID-19 Patients by Nearly 30%

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today announced new preclinical research published in Investigative Ophthalmology & Visual Science finding Niagen® (patented nicotinamide riboside, or NR) prevented light-induced retinal damage in mice.

New Preclinical Study Finds Niagen® Prevents Light-Induced Retinal Damage in Mice

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting at the LD 500 investor conference.

ChromaDex to Present at the LD 500 Virtual Investor Conference

Apple

Aldeyra Therapeutics

Chevron

Home Depot

Intel

Johnson & Johnson

Merck

Nuveen Quality Municipal Income Fund

Verizon

Week 35 MDA Breakout Forecast: Short-Term Picks To Give You An Edge

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today announced the 11th published human trial on its patented NAD-boosting nutrient Niagen®, further highlighting its potential to support cardiovascular health in humans.

New Pilot Study Indicates Niagen® May Reduce Inflammatory Cytokines in Stage D Heart Failure Patients

ChromaDex Corporation (CDXC) CEO Rob Fried on Q2 2020 Results - Earnings Call Transcript

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today reported second quarter 2020 financial results.

ChromaDex Corporation Reports Second Quarter 2020 Financial Results

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Thurs.

ChromaDex to Report Second Quarter 2020 Financial Results on Thursday, August 6, 2020

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #AutismResearch--ChromaDex Corp. (NASDAQ:CDXC) today announced the results of a new preclinical study published in Nature Scientific Reports investigating the role of Niagen® (patented nicotinamide riboside) in addressing social deficits in Autism Spectrum Disorder (ASD).

New Preclinical Study Finds Niagen® Corrects Social Deficits in Mouse Model of Autism

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today announced the Company has signed its 200th material transfer agreement (MTA) through its global ChromaDex External Research Program (CERP™). The program provides Niagen® (nicotinamide riboside) ingredient and placebos at no cost as well as technical expertise and intellectual property support to leading research institutions and universities around the world, advancing the evidence and understanding of the health impact of increa

ChromaDex External Research Program (CERP™) Achieves 200th Material Transfer Agreement for Niagen® (Nicotinamide Riboside) Research

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today announced the latest preclinical findings indicating Niagen® (patented nicotinamide riboside) inhibits replication of a form of Coronavirus, the virus that causes COVID-19 infection, in mouse cells. The preclinical study results were published July 8 on scientific publishing website bioRxiv.org. The research conducted jointly at the University of Iowa, Oregon Health & Science University, and the University of Kansas previousl

ChromaDex Announces New Study Results Highlighting Promising Anti-Viral Effects of Niagen® in Coronavirus Cell Model

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) announced today the initiation of a preclinical study in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH). This study will assess if administration of Niagen® (nicotinamide riboside, or NR) can reduce viral burden and inflammation in mouse and hamster models of COVID-19. ChromaDex’s patent-protected NR is a unique nutrient that supports cellular

ChromaDex and the NIH-NIAID Rocky Mountain Laboratories Announce Study to Assess the Therapeutic Potential of Niagen® in COVID-19 Animal Models

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today announced the results of multiple new preclinical studies that illustrate the multifaceted potential of Niagen® (nicotinamide riboside or NR) in bolstering cellular health to counteract or reduce progression of numerous degenerative conditions. The proven ability of Niagen® to raise NAD+ levels was found to contribute to positive effects in preclinical models of aging, fertility, and circadian rhythms, and in a clinical study on

New Preclinical Findings Suggest Boosting NAD+ with Niagen® Holds Potential for Slowing Aging Process and Reducing Metabolic Damage

ChromaDex Corporation's (CDXC) CEO Rob Fried on Q1 2020 Results - Earnings Call Transcript

ChromaDex (CDXC) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

ChromaDex (CDXC) Jumps: Stock Rises 7.7%

ChromaDex Partners with Matakana Health Limited to Bring Tru Niagen to Australia

Cellular Health Market Leader Tru Niagen® Launches Online in Australia

LOS ANGELES, March  12, 2020  (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) seeks to correct statements made by an unaffiliated third-party, Merkel Media Group on behalf of its unnamed client, implying unsupported health claims about Tru Niagen and COVID-19. There are no published human clinical studies evaluating the effects of Tru Niagen® supplementation with the Coronavirus. As such, no health claims can be made related to COVID-19 at this time.

News for ChromaDex Stock (CDXC)